| US2940972A
              (en) | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives | 
        
          | US4666828A
              (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease | 
        
          | US4683202A
              (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences | 
        
          | US4801531A
              (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis | 
        
          | US5272057A
              (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase | 
        
          | US5192659A
              (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes | 
        
          | GB9125001D0
              (en)
            
            * | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds | 
        
          | CA2160786A1
              (en) | 1993-05-14 | 1994-11-24 | James C. Marsters, Jr. | Ras farnesyl transferase inhibitors | 
        
          | US5700823A
              (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers | 
        
          | US6331555B1
              (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers | 
        
          | EP0951541B1
              (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | 
        
          | US6218529B1
              (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer | 
        
          | TW472045B
              (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation | 
        
          | EA002600B1
              (ru) | 1997-05-28 | 2002-06-27 | Авентис Фармасьютикалз Продактс Инк. | ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ р56 | 
        
          | UA71555C2
              (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives | 
        
          | EP1147094A1
              (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists | 
        
          | CN1373763A
              (zh)
            
            * | 1999-09-15 | 2002-10-09 | 沃尼尔·朗伯公司 | 作为激酶抑制剂的蝶啶酮 | 
        
          | DE10013318A1
              (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate | 
        
          | WO2002076985A1
              (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | 
        
          | JP2003013463A
              (ja)
            
            * | 2001-06-28 | 2003-01-15 | Works 21:Kk | マンホール施工方法 | 
        
          | CA2469813C
              (en) | 2001-12-18 | 2009-02-24 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | 
        
          | US7402585B2
              (en) | 2001-12-24 | 2008-07-22 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases | 
        
          | JP2003213463A
              (ja) | 2002-01-17 | 2003-07-30 | Sumitomo Chem Co Ltd | 金属腐食防止剤および洗浄液 | 
        
          | CA2480800C
              (en) | 2002-04-08 | 2008-09-23 | Mark T. Bilodeau | Inhibitors of akt activity | 
        
          | US7265378B2
              (en) | 2002-07-10 | 2007-09-04 | E. I. Du Pont De Nemours And Company | Electronic devices made with electron transport and/or anti-quenching layers | 
        
          | US7825132B2
              (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma | 
        
          | EP1549614A4
              (en) | 2002-10-03 | 2008-04-16 | Targegen Inc | VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION | 
        
          | AR043059A1
              (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos | 
        
          | US7098332B2
              (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones | 
        
          | WO2004065378A1
              (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation | 
        
          | EP1620413A2
              (en) | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods | 
        
          | CN102584813B
              (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 | 
        
          | KR101111464B1
              (ko) | 2003-05-23 | 2012-02-21 | 아에테르나 젠타리스 게엠베하 | 신규한 피리도피라진 및 이를 포함하는 키나제 조절제로서의 약제 | 
        
          | DE10323345A1
              (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren | 
        
          | WO2005007099A2
              (en) | 2003-07-10 | 2005-01-27 | Imclone Systems Incorporated | Pkb inhibitors as anti-tumor agents | 
        
          | EP1646383A4
              (en) | 2003-07-21 | 2009-03-25 | Bethesda Pharmaceuticals Inc | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | 
        
          | WO2005012288A1
              (en)
            
            * | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc | Bicyclic imidazol derivatives against flaviviridae | 
        
          | DE602004008312T2
              (de) | 2003-10-17 | 2008-04-17 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie | 
        
          | EP1692085A4
              (en) | 2003-11-07 | 2010-10-13 | Novartis Vaccines & Diagnostic | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | 
        
          | US7855207B2
              (en) | 2003-11-20 | 2010-12-21 | Janssen Pharmaceutica, Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | 
        
          | KR100861515B1
              (ko) | 2003-11-24 | 2008-10-02 | 에프. 호프만-라 로슈 아게 | 피라졸릴 및 이미다졸릴 피리미딘 | 
        
          | WO2005061463A1
              (en) | 2003-12-23 | 2005-07-07 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators | 
        
          | US7205316B2
              (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | 
        
          | US7098222B2
              (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | 
        
          | NZ553087A
              (en) | 2004-08-31 | 2010-12-24 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-raf inhibitors | 
        
          | US7268231B2
              (en) | 2004-10-14 | 2007-09-11 | Hoffmann-La Roche Inc. | 1,5-Naphthyridine azolinone | 
        
          | ES2425567T3
              (es) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Método de tratamiento o profilaxis | 
        
          | CA2597447C
              (en) | 2005-02-14 | 2014-03-25 | Bionomics Limited | Novel tubulin polymerisation inhibitors | 
        
          | US9271963B2
              (en) | 2005-03-03 | 2016-03-01 | Universitat Des Saarlandes | Selective inhibitors of human corticosteroid synthases | 
        
          | US20090156617A1
              (en) | 2005-05-12 | 2009-06-18 | Northrup Alan B | Tyrosine kinase inhibitors | 
        
          | CN101223170A
              (zh) | 2005-05-18 | 2008-07-16 | 惠氏公司 | Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法 | 
        
          | GB0513692D0
              (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions | 
        
          | AU2006283846B2
              (en) | 2005-08-26 | 2012-04-05 | Merck Serono Sa | Pyrazine derivatives and use as PI3K inhibitors | 
        
          | WO2007054556A1
              (de) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen | 
        
          | US8217042B2
              (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases | 
        
          | EP1790342A1
              (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege | 
        
          | ES2612377T3
              (es) | 2005-12-21 | 2017-05-16 | Janssen Pharmaceutica N.V. | Triazolopiridazinas como moduladores de tirosina cinasas | 
        
          | EP2024342A2
              (en) | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds | 
        
          | GB0609621D0
              (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal | 
        
          | CA2653117A1
              (en) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituted pteridines substituted with a four-membered heterocycle | 
        
          | WO2008003702A2
              (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine h4 receptor | 
        
          | JP2008127446A
              (ja) | 2006-11-20 | 2008-06-05 | Canon Inc | 1,5−ナフチリジン化合物及び有機発光素子 | 
        
          | MX2009006466A
              (es) | 2006-12-13 | 2009-06-26 | Schering Corp | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | 
        
          | JP2010514695A
              (ja) | 2006-12-21 | 2010-05-06 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物および方法およびそのための適応症 | 
        
          | WO2008078091A1
              (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors | 
        
          | CN101652352A
              (zh) | 2006-12-22 | 2010-02-17 | 诺瓦提斯公司 | 用于抑制pdk1的喹唑啉类 | 
        
          | KR20080062876A
              (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 | 
        
          | EP1990342A1
              (en) | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | 
        
          | JP2010526823A
              (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのキノキサリン誘導体 | 
        
          | JP2010529031A
              (ja) | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害剤としてのナフチリジン誘導体 | 
        
          | AR066879A1
              (es) | 2007-06-08 | 2009-09-16 | Novartis Ag | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | 
        
          | KR20130008625A
              (ko) | 2007-06-20 | 2013-01-22 | 미쓰비시 타나베 파마 코퍼레이션 | 신규한 말론산술폰아미드 유도체 및 그 의약 용도 | 
        
          | WO2008155378A1
              (en) | 2007-06-21 | 2008-12-24 | Janssen Pharmaceutica Nv | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline | 
        
          | WO2009009016A1
              (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy | 
        
          | AR068054A1
              (es) | 2007-08-08 | 2009-11-04 | Smithkline Beecham Corp | Compuestos de pirrolopirimidina | 
        
          | JP2010535804A
              (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害薬としてのキノキサリン誘導体 | 
        
          | WO2009019518A1
              (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect | 
        
          | US20090054304A1
              (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease | 
        
          | JP5480813B2
              (ja) | 2007-11-16 | 2014-04-23 | インサイト・コーポレイション | Janusキナーゼ阻害剤としての置換複素環 | 
        
          | WO2009137378A2
              (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer | 
        
          | WO2009141386A1
              (en) | 2008-05-23 | 2009-11-26 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors | 
        
          | EP2356116A1
              (en) | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines | 
        
          | CN102361863B
              (zh) | 2009-01-21 | 2014-12-03 | 巴斯利尔药物股份公司 | 新的二环抗生素 | 
        
          | JP2012516847A
              (ja) | 2009-02-02 | 2012-07-26 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 | 
        
          | TW201041888A
              (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor | 
        
          | AU2010258294B2
              (en) | 2009-06-12 | 2015-07-30 | Abivax | Compounds useful for treating cancer | 
        
          | CA2772714C
              (en) | 2009-09-03 | 2017-09-26 | Bioenergenix | Heterocyclic compounds for the inhibition of pask | 
        
          | CN102596932A
              (zh) | 2009-09-04 | 2012-07-18 | 拜耳医药股份有限公司 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 | 
        
          | US20110123545A1
              (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases | 
        
          | EP2332939A1
              (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | 
        
          | SG10201502484SA
              (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin | 
        
          | GB201007286D0
              (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds | 
        
          | WO2011146591A1
              (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof | 
        
          | US9096590B2
              (en) | 2010-05-24 | 2015-08-04 | Intellikine Llc | Substituted benzoxazoles as PI3 kinase inhibitors | 
        
          | GB201020179D0
              (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds | 
        
          | CN102532141A
              (zh) | 2010-12-08 | 2012-07-04 | 中国科学院上海药物研究所 | [1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途 | 
        
          | CN103476777B
              (zh) | 2011-01-31 | 2015-05-27 | 诺瓦提斯公司 | 新杂环衍生物 | 
        
          | JP2014510265A
              (ja) | 2011-02-02 | 2014-04-24 | アムジェン  インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 | 
        
          | CN103491962B
              (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 | 
        
          | WO2012118492A1
              (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors | 
        
          | EP2702173A1
              (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment | 
        
          | CA2846574C
              (en) | 2011-08-26 | 2020-07-07 | Neupharma, Inc. | Quinoxaline sulfonamide derivates for use as kinase inhibitors | 
        
          | CN104080455B
              (zh) | 2011-09-14 | 2018-07-31 | 润新生物公司 | 某些化学实体、组合物及方法 | 
        
          | US9249110B2
              (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors | 
        
          | HK1201065A1
              (en) | 2011-10-04 | 2015-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k | 
        
          | GB201118652D0
              (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds | 
        
          | GB201118656D0
              (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds | 
        
          | JO3210B1
              (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة | 
        
          | GB201118675D0
              (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds | 
        
          | CN104039790B
              (zh) | 2011-10-28 | 2016-04-13 | 诺华股份有限公司 | 嘌呤衍生物及它们在治疗疾病中的应用 | 
        
          | GB201118654D0
              (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds | 
        
          | BR112014021897B1
              (pt) | 2012-03-08 | 2022-06-14 | Astellas Pharma Inc | Método, kit, conjunto de iniciadores e conjuntos de sondas para detectar um gene de fusão composto por um gene fgfr3 e um gene tacc3 | 
        
          | GB201209613D0
              (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds | 
        
          | GB201209609D0
              (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds | 
        
          | US20150203589A1
              (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof | 
        
          | AU2014207342C1
              (en) | 2013-01-18 | 2019-04-04 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma | 
        
          | GB201307577D0
              (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds | 
        
          | EP3027623A4
              (en) | 2013-08-02 | 2017-03-01 | Ignyta, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS | 
        
          | US9221804B2
              (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt | 
        
          | RU2715893C2
              (ru) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r | 
        
          | JO3512B1
              (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | 
        
          | SMT202100115T1
              (it) | 2014-03-26 | 2021-05-07 | Astex Therapeutics Ltd | Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro | 
        
          | JOP20200201A1
              (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين | 
        
          | JP6774421B2
              (ja) | 2015-02-19 | 2020-10-21 | フュージョン ファーマシューティカルズ インク. | がんの治療のための方法、組成物、及びキット | 
        
          | US10478494B2
              (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |